Back to top

Novavax (NVAX) Catches Eye: Stock Jumps 7.6%

Read MoreHide Full Article

Novavax, Inc. (NVAX - Free Report) was a big mover last session, as the company saw its shares rise nearly 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 43.2% in the past one-month time frame.

The move came after the company reported the initiation of phase 2 clinical trial of NanoFlu in older adults.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Novavax. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Novavax currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.  

A better-ranked stock in the Medical - Biomedical and Genetics industry is Anika Therapeutics Inc. (ANIK - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is NVAX going up? Or down? Predict to see what others think: Up or Down

The Hottest Tech Mega-Trend of All

Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Novavax, Inc. (NVAX) - free report >>

Anika Therapeutics Inc. (ANIK) - free report >>

More from Zacks Tale of the Tape

You May Like